SQSTM1 and ovarian carcinoma: Concomitant with inhibiting cathepsin B and increasing p62 levels, bortezomib also stimulated ERK phosphorylation in ovarian cancer cells (Figure 5d), endometrial cancer Ishikawa cells, and hepatocellular carcinoma HepG2 cells (Supplementary Figure 5).